Your purpose is our purpose

Get Started with a Customized Clinical Solution

Our Expertise

  • 650+

    Drugs supported: all modalities, routes of administration and therapeutic areas

  • 6650+

    PK, PD, TK, QTC translational analyses

  • 400+

    PopPK and E-R modeling, dose, and trial simulations

  • 500+

    Clients supported

Why Allucent?

Allucent was specifically built to meet the very unique needs of the small to mid-size biotech. Our range of capabilities is equivalent to that of large contract research organizations, but with the expertise and specialization of niche CROs. Through extraordinary attention to detail and focused operational efficiency we deliver to your milestones. We anticipate and mitigate problems before they happen and our nimble philosophy allows us to pivot to your needs quickly.

Therapeutic Proficiency

You treat the most complex and challenging diseases. We’ve assembled expert, multidisciplinary teams to support your specific therapeutic need.

Exceptional Clinical Trial Delivery

Allucent’s flexible clinical development and regulatory solutions enable our partners to successfully navigate the complexities of managing and conducting early and late-stage multi-national programs

Robust Consulting

From biostatistical consulting to regulatory strategy and clinical pharmacology, Allucent has a deep bench of experts to tackle these critically important gates to improve efficiencies and take your drug to market faster.

Clinical Pharmacology

Allucent’s clinical pharmacology team helps you meet key milestones with strategic planning, PK/PD studies, dose optimization, MIDD, and regulatory submissions. Our expertise accelerates timelines, improves decision-making, and mitigates risk.

Smarter Drug Development for Faster Approval

We integrate preclinical research with clinical applications to optimize dosing, streamline trials, and ensure regulatory success. Our DMPK expertise supports lead optimization, IND strategies, and first-in-human dose selection.

Enhance Drug Development with Modeling & Simulation

M&S optimizes dosing, improves success rates, and ensures accurate labeling and prescribing for better patient outcomes.

Unlock the Full Potential of Your Data with End-to-End PK

From study design to analysis, we translate complex PK data into actionable strategies that enhance therapeutic outcomes and regulatory approval.

Embedded Pharmacologists

Our clinical pharmacologists integrate seamlessly into your team, driving efficient, data-driven decisions, improving transparency, and reducing project delays

Areas of Expertise

  • Project Optimus
  • Patient Diversity & Special Populations
  • Pediatrics and Rare Disease
  • Data Programming and analytics

Why We Excel?

  • Full breadth of services
  • Translational pharmacology
  • Pharmacometrics
  • Data programming and analytics

Testimonials

Having an ‘embedded’ Clinical Pharmacologist from Allucent does not feel any different than an internal colleague. They attend clinical teams, provide input to the clinical pharmacology strategy, and participate into functional reviews. Experience has been very positive and success will depend on how well the external colleague can feel part of the team (e.g., ask key questions, provide independent insights, leverage experience from others).

HEAD OF CLINICAL PHARMACOLOGY, LEADING BIOTECH

We would not have been successful in this submission without you. Your team has come together to successfully author the PK reports for the Phase 1 studies and the clinical pharmacology and bioanalytical methods Module 2 summaries. We appreciate your diligence and attention to detail during the authoring process.

VICE PRESIDENT & HEAD OF REGULATORY AFFAIRS, LEADING BIOTECH

Therapeutic Expertise

The Allucent Centers of Expertise (ACEs) are designed, structured, and resourced to deliver comprehensive trial and regulatory strategy; effective patient-focused recruitment plans; and solutions that meet your specific needs.

Oncology & Hematology
Rare Disease
Cell & Gene Therapy
Neuroscience & Psychiatry
Infectious Disease & Vaccine
Allergy & Asthma
Autoimmune & Inflammation

Leadership

Katy Moore, PharmD,RPh
President
Lisa Benincosa, PhD
SVP Clinical Pharmacology Strategy
Alex MacDonald, PhD
VP, Global Head of Model-Informed Drug Development

About Us

A Fully Integrated Global Company

Allucent delivers innovative strategies and robust solutions based on over 30 years of background in regulatory trends, therapeutic experience, and operational expertise. We share small and mid-sized companies’ deep commitment to supporting breakthrough science by partnering with them to navigate the complexities of delivering novel treatments to patients.

With offices across North America, Europe, and the Middle East, Allucent has experience conducting trials in more than 75 countries, focusing on some of the most complex development areas. Globally, Allucent has worked on more than 825 clinical trials, with oncology representing the majority.

Speak with an Expert

Frequently Asked Questions

A lot, actually. Allucent was specifically built to meet the very unique needs of the small to mid-size Biotech. Our range of capabilities is equivalent to that of large contract research organizations, but with the expertise and specialization of niche CROs. Through extraordinary attention to detail and focused operational efficiency we deliver to your milestones. We anticipate and mitigate problems before they happen and our nimble philosophy allows us to pivot to your needs quickly.

The most efficient and effective way to evaluate why Allucent is the best CRO for your drug development program is to click this link. It takes you to a form where you answer a few questions, then one of our A-Team experts will reach out to you within 24 hours. That kicks off a process where we get a comprehensive understanding of your needs, and we come back to you with a detailed proposal for how Allucent will be the best partner to ensure your success.

The Allucent brand is only 3 years old. In actuality, we’ve been around for almost 40 years. After a series of acquisitions and mergers, Allucent is purpose-built and the sum total of CATO Research (1988), SMS Oncology (1994), Pharm-Olam (2007), Nuventra (2008), Array Biostatistics (2012), and CATO-SMS (2019).

Get Started with a Customized Clinical Solution